The experimental therapy Bravyl significantly reduced the spread of toxic TDP-43 protein clumps in a cell model of ALS.

Worrying about symptom progression a year after her diagnosis, columnist Dagmar Munn decided to develop her own resilience ...

The results of CardinALS showed utreloxastat failed to meet its main and secondary goals, including several disease-related ...

Data from over 8,000 ALS patients will be fed into Unlearn's Digital Twin Generator, an AI platform that creates duplicates ...

Like many ALS patients, I had a difficult time accepting assistive devices into my life. In my case, a pair of ankle-foot ...

Columnist Juliet Taylor's late husband, Jeff, always made Christmas special. To honor his memory, she carries on their ...

The delay in diagnosing ALS means treatment and supportive care is received later, which can have a significant impact on ...

The U.S. Food and Drug Administration (FDA) signaled that it may be willing to consider granting accelerated approval to ...

Growing up in rural areas, having younger parents, and having less education may all be environmental risk factors for ALS, ...

MN-166 (ibudilast) appears to benefit ALS patients over up to one year of use, an interim Phase 2b/3 trial analysis suggests.

The first ALS patient was dosed in a Phase 1 trial of Quralis' first-in-class therapy QRL-101, which is still enrolling at a ...

Neuralink's brain-computer interface will be tested in Canada, with Toronto's University Health System seeking patients for ...